Ketamine: Leading us into the future for development of antidepressants.
Allosteric Regulation
Animals
Antidepressive Agents
/ pharmacology
Depressive Disorder, Major
/ drug therapy
Depressive Disorder, Treatment-Resistant
/ drug therapy
Drug Development
Hippocampus
/ drug effects
Humans
Ketamine
/ pharmacology
Molecular Targeted Therapy
Neural Pathways
Receptors, GABA-A
/ drug effects
Receptors, N-Methyl-D-Aspartate
/ drug effects
Receptors, Opioid, mu
/ drug effects
Depression
Ketamine
Negative allosteric modulators
Receptors
Ventral hippocampus
α5-containing GABA(A)
Journal
Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872
Informations de publication
Date de publication:
06 04 2020
06 04 2020
Historique:
received:
31
10
2019
revised:
31
01
2020
accepted:
31
01
2020
pubmed:
6
2
2020
medline:
26
5
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Numerous randomized double-blind clinical trials have consistently shown that that a single intravenous administration of a subanesthetic dose of ketamine to treatment-resistant depressed patients significantly improved depressive symptomatology rapidly, within two hours, with the effect lasting up to seven days. Despite its very promising effects, ketamine has long been associated with potential for abuse as it can cause psychotropic side effects, such as hallucinations, false beliefs, and severe impairments in judgment and other cognitive processes. Consequently, within the last two decades preclinical research has been carried out aimed at understanding its mechanisms of action and the brain circuits involved in ketamine's antidepressant effects, both of which are discussed in this review. Furthermore, with the hippocampus being a key target for ketamine's beneficial antidepressant effects, we and others have begun to examine behavioral and neurochemical effects of drugs that act selectively on the hippocampus due to the preferential location of their receptor targets. Such drugs are negative allosteric modulators (NAMs) and positive allosteric modulator (PAM) of the α5-GABA
Identifiants
pubmed: 32023492
pii: S0166-4328(19)31598-0
doi: 10.1016/j.bbr.2020.112532
pmc: PMC7890296
mid: NIHMS1558555
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Gabra5 protein, mouse
0
Gabra5 protein, rat
0
Receptors, GABA-A
0
Receptors, N-Methyl-D-Aspartate
0
Receptors, Opioid, mu
0
Ketamine
690G0D6V8H
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112532Subventions
Organisme : BLRD VA
ID : I01 BX000559
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH090067
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH113899
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Neuroscience. 2009 Aug 4;162(1):195-207
pubmed: 19401219
Psychol Med. 2012 Sep;42(9):1997-2010
pubmed: 22273480
J Neurosci. 2007 Oct 24;27(43):11496-500
pubmed: 17959792
Neuroscience. 2003;119(1):19-31
pubmed: 12763065
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109668
pubmed: 31207274
Neural Plast. 2016;2016:8056370
pubmed: 26881133
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E3007-E3016
pubmed: 29531088
Brain Res. 1999 Mar 20;822(1-2):265-70
pubmed: 10082908
Biol Psychiatry. 2008 Feb 15;63(4):349-52
pubmed: 17643398
J Psychiatr Res. 2019 Jun;113:125-136
pubmed: 30974339
J Neurosci. 2019 Jan 30;39(5):788-801
pubmed: 30523065
J Affect Disord. 2014 Mar;156:1-7
pubmed: 24314926
J Psychiatr Res. 2019 Mar;110:166-171
pubmed: 30641350
J Physiol. 2011 Oct 15;589(Pt 20):4885-901
pubmed: 21825029
J Clin Psychiatry. 2007;68 Suppl 10:8-10
pubmed: 17900203
Biol Psychiatry. 2013 Aug 15;74(4):250-6
pubmed: 22840761
Eur J Pharmacol. 1990 Aug 21;185(1):1-10
pubmed: 2171955
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
pubmed: 16894061
J Psychiatr Res. 2010 Oct;44(13):799-807
pubmed: 20122698
Am J Psychiatry. 2016 Aug 1;173(8):816-26
pubmed: 27056608
ACS Chem Neurosci. 2019 May 15;10(5):2088-2090
pubmed: 30920790
J Affect Disord. 2014 Apr;159:56-61
pubmed: 24679390
Expert Rev Neurother. 2019 Jan;19(1):83-92
pubmed: 30513009
Neuron. 2019 Mar 6;101(5):774-778
pubmed: 30844397
Am J Psychiatry. 2018 Dec 1;175(12):1205-1215
pubmed: 30153752
JAMA Psychiatry. 2018 Feb 1;75(2):139-148
pubmed: 29282469
Curr Neuropharmacol. 2017;15(1):71-86
pubmed: 26830964
Am J Psychiatry. 1997 Jun;154(6):805-11
pubmed: 9167508
Neuroscience. 2015 Apr 2;290:49-60
pubmed: 25595985
Biol Psychiatry. 2013 Jun 15;73(12):1125-32
pubmed: 23453290
Pharmacol Biochem Behav. 2014 Jan;116:137-41
pubmed: 24316345
Neuropsychopharmacology. 2015 Oct;40(11):2499-509
pubmed: 25900119
Neurosci Lett. 1998 Jun 19;249(2-3):99-102
pubmed: 9682826
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3662-7
pubmed: 14993607
Neuropharmacology. 1996;35(9-10):1331-5
pubmed: 9014149
Biol Psychiatry. 2019 Mar 15;85(6):e25-e27
pubmed: 30545521
Neuroscience. 2010 Jan 20;165(2):601-11
pubmed: 19854244
J Am Assoc Lab Anim Sci. 2013 Sep;52(5):567-70
pubmed: 24041212
Cereb Cortex. 2008 Jun;18(6):1260-71
pubmed: 17951598
eNeuro. 2017 Mar 7;4(1):
pubmed: 28275719
Mol Psychiatry. 2019 Dec;24(12):1816-1832
pubmed: 30894661
Neuropharmacology. 2012 Jan;62(1):35-41
pubmed: 21907221
Biol Psychiatry. 2018 Jan 1;83(1):2-4
pubmed: 29173705
J Neurosci. 2002 Feb 1;22(3):684-97
pubmed: 11826098
J Neural Transm (Vienna). 2017 Jan;124(1):145-158
pubmed: 27848034
Neuropharmacology. 1987 Sep;26(9):1253-60
pubmed: 2823161
Int J Neuropsychopharmacol. 2019 Feb 1;22(2):85-92
pubmed: 29961822
Depress Anxiety. 2014 Apr;31(4):335-43
pubmed: 24668760
J Comp Neurol. 2002 Sep 2;450(4):345-65
pubmed: 12209848
Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2656-2662
pubmed: 31941713
Nat Med. 2016 Mar;22(3):238-49
pubmed: 26937618
Int J Neuropsychopharmacol. 2017 Jun 1;20(6):504-509
pubmed: 28339593
Neuropsychopharmacology. 1997 May;16(5):357-72
pubmed: 9109107
Int J Neuropsychopharmacol. 2019 Feb 1;22(2):119-135
pubmed: 30445512
Biol Psychiatry. 2014 Dec 15;76(12):927-36
pubmed: 24931705
J Neurobiol. 2004 Aug;60(2):236-48
pubmed: 15266654
Science. 2019 Apr 12;364(6436):
pubmed: 30975859
Mol Psychiatry. 2016 Sep;21(9):1298-308
pubmed: 26619811
Pharmacol Rev. 2018 Jul;70(3):621-660
pubmed: 29945898
Behav Brain Res. 2016 Oct 1;312:305-12
pubmed: 27343934
Nature. 2018 Feb 14;554(7692):317-322
pubmed: 29446381
Nature. 2016 May 04;533(7604):481-6
pubmed: 27144355
J Neurophysiol. 2006 Oct;96(4):2134-8
pubmed: 16837666
ILAR J. 2011;52(3):366-78
pubmed: 23382150
Science. 2010 Aug 20;329(5994):959-64
pubmed: 20724638
Trends Pharmacol Sci. 2011 Sep;32(9):507-13
pubmed: 21700346
J Neurophysiol. 2006 May;95(5):2796-807
pubmed: 16452257
Br J Psychiatry. 2012 Feb;200(2):97-106
pubmed: 22297588
Int J Neuropsychopharmacol. 2017 Apr 1;20(4):354-358
pubmed: 27806991
J Neurosci. 1997 Apr 15;17(8):2921-7
pubmed: 9092613
J Affect Disord. 2018 May;232:310-315
pubmed: 29501990
J Neurophysiol. 2009 Mar;101(3):1179-91
pubmed: 19073796
Biol Psychiatry. 2016 Sep 15;80(6):448-456
pubmed: 26957131
Acta Psychiatr Scand. 2019 Aug;140(2):182-183
pubmed: 31251388
Brain Res. 1981 Jul 27;217(1):150-4
pubmed: 7260612
J Comp Neurol. 2002 Jan 28;443(1):43-55
pubmed: 11793346
Am J Psychiatry. 2019 Jun 1;176(6):422-424
pubmed: 31109197
Eur J Pharmacol. 1994 Sep 22;263(1-2):1-7
pubmed: 7821340
Neuropsychopharmacology. 2004 Mar;29(3):566-79
pubmed: 14627997
Nature. 2011 Jun 15;475(7354):91-5
pubmed: 21677641
J Psychiatr Res. 2014 Nov;58:161-6
pubmed: 25169854
Psychol Med. 2015 Dec;45(16):3571-80
pubmed: 26266877
Biol Psychiatry. 2000 Feb 15;47(4):351-4
pubmed: 10686270
Biol Psychiatry. 1999 Nov 1;46(9):1181-91
pubmed: 10560024
J Comp Neurol. 1991 Nov 22;313(4):574-86
pubmed: 1783682
Anesthesiology. 1998 Jan;88(1):82-8
pubmed: 9447860
Neuropharmacology. 2013 Jul;70:27-34
pubmed: 23337256
F1000Res. 2015 Dec 02;4:
pubmed: 26918135
Am J Psychiatry. 2004 Nov;161(11):1957-66
pubmed: 15514393
Behav Brain Res. 2019 Sep 2;369:111928
pubmed: 31034850
JAMA Psychiatry. 2019 Mar 1;76(3):337-338
pubmed: 30624551
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8980-5
pubmed: 12084936
Transl Psychiatry. 2015 Sep 01;5:e632
pubmed: 26327690
Psychopharmacology (Berl). 2015 Sep;232(17):3123-33
pubmed: 25986748
Mol Pharmacol. 1998 Nov;54(5):928-33
pubmed: 9804628
Neuroscience. 2002;114(3):769-79
pubmed: 12220577
Eur Neuropsychopharmacol. 1993 Jun;3(2):127-35
pubmed: 8364348
Eur J Pharmacol. 1989 Mar 29;162(3):483-90
pubmed: 2663525
J Psychopharmacol. 2015 May;29(5):596-607
pubmed: 25691504
Neuropsychopharmacology. 2018 Aug;43(9):1900-1907
pubmed: 29802366
Neurotherapeutics. 2017 Jul;14(3):716-727
pubmed: 28585221
Mol Neuropsychiatry. 2019 Apr;5(2):84-97
pubmed: 31192221
Brain Res. 1977 Mar 25;124(2):197-224
pubmed: 402984
Biol Psychiatry. 2018 Jul 1;84(1):65-75
pubmed: 29395043
Biol Psychiatry. 2018 Jan 1;83(1):18-28
pubmed: 28651788
Neuroreport. 1995 Apr 19;6(6):869-72
pubmed: 7612873
Dialogues Clin Neurosci. 2014 Mar;16(1):11-27
pubmed: 24733968
Nat Commun. 2018 Sep 3;9(1):3576
pubmed: 30177704
Brain Res Mol Brain Res. 2000 Sep 15;80(2):228-32
pubmed: 11038255
Biol Psychiatry. 2011 Apr 15;69(8):754-61
pubmed: 21292242
Annu Rev Neurosci. 2004;27:279-306
pubmed: 15217334
Psychiatr Serv. 2014 Aug 1;65(8):977-87
pubmed: 24789696
Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8467-72
pubmed: 15159546
J Affect Disord. 2009 Jul;116(1-2):4-11
pubmed: 19007996
Am J Psychiatry. 2019 Jun 1;176(6):428-438
pubmed: 31109201
Curr Opin Behav Sci. 2018 Oct;23:36-41
pubmed: 30038955
J Neurosci. 1992 Mar;12(3):1040-62
pubmed: 1312131
Neuroscience. 2000;101(4):815-50
pubmed: 11113332
Lancet Psychiatry. 2018 Jan;5(1):65-78
pubmed: 28757132
J Comp Neurol. 2006 Nov 20;499(3):458-70
pubmed: 16998906